Brand & Product Security

Articles

Why well-organized documentation is critical at every stage of the process.

Technically Speaking: Quality Documentation is One of the Best Ways to Boost Performance

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Gaurav Gupta, managing director and head of R&D at Kotter, details the types of regulatory pressures and factors surrounding rising R&D costs that will affect the pharmaceutical industry.

Key Challenges Facing the Pharma Industry in 2025

In the first part of this roundtable discussion, a panel of subject matter experts introduce themselves, while discussing why the pharma supply chain sees value in this technology and why its use has fluctuated over the past decade.

Peer Exchange: An Overview of RFID Within the Pharmaceutical Industry (Episode 1)

In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.

Understanding the FDA's Exemption for DSCSA Compliance

In this Q&A, Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy Compounding discuss the challenges faced by patients and healthcare providers due to drug shortages, particularly for semaglutide and other medications. 

Is Compounding the Answer to the Semaglutide Shortage? Experts Weigh In

Albert Thigpen, co-founder, Talentwise Consulting, discusses the valuable buckets pertaining to the PBM space. 

Access Insights 2024: Pharmacy Benefit Management Trends

Albert Thigpen, co-founder, Talentwise Consulting, offers highlights of the drug commercialization panel that he participated in.

Access Insights 2024: Key Nuggets Surrounding the Chess Endgame

A professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business.

With great power comes great responsibility. In this case, tackling these obstacles is vital to making sure that the positives of GLP-1s are not outweighed by the downfalls of improper waste disposal.

The Rise of GLP-1 Drugs and the Challenges of Proper Disposal

The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.

Facing Potential Drug Shortages, FDA Delays Enforcement of DSCSA Compliance Deadline, with Stipulations

A deep dive into the future of patient service programs and the value of transparency throughout the process.

Legal & Regulatory